Creavo enrols final patient in largest magnetocardiography trial of its kind

Trial tests the viability of Creavo’s MCG device at five major emergency departments across the UK

The trial will test Creavo's magnetocardiography device

Creavo Medical Technologies has completed patient enrolment in its multi-centre study.

Involving 750 patients across five of the UK’s-largest emergency departments - Sheffield, Nottingham, Bristol, Leicester and London’s St George’s - the study has been conducted to assess the accuracy of Creavo’s magnetocardiography (MCG) device in identifying those at low risk of ischaemic heart disease.

The device, which performs a non-invasive scan within minutes at the patient’s bedside, has been designed to aid clinicians meet a clinical need; to quickly rule out ischaemia-related heart problems at the point of admission to emergency departments.

Identifying these patients early can potentially reduce patient anxiety and save hospitals valuable time, resources and bed space. Financially, the device also has the potential to save the UK healthcare system up to £200m a year.

Steve Parker, chief executive at Creavo, said: “Finalising this important study is a major milestone for Creavo as we work towards our goal of offering rapid diagnostic solutions that improve patient outcomes and meet the needs of healthcare professionals.

“This study will give us important information and I’d like to thank the experienced healthcare professionals and patients who have supported and participated to make this trial possible.

“Feedback from the users has been positive and we’re looking forward to releasing the results in due course.”

Companies